Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-11 4:43 pm Purchase | 2026-03-09 | 13D | SAB Biotherapeutics, Inc. SABS | RA CAPITAL MANAGEMENT L.P. | 5,166,424 9.900% | 764,924 (+17.38%) | Filing History |
| 2026-03-10 4:38 pm Purchase | 2026-03-06 | 13D | Solid Biosciences Inc. SLDB | RA CAPITAL MANAGEMENT L.P. | 9,663,926 9.900% | 1,666,416 (+20.84%) | Filing History |
| 2026-03-06 4:28 pm Purchase | 2026-03-04 | 13D | Tyra Biosciences, Inc. TYRA | RA CAPITAL MANAGEMENT L.P. | 12,266,575 21.200% | 366,787 (+3.08%) | Filing History |
| 2026-03-02 4:25 pm Purchase | 2026-02-26 | 13D | Bicara Therapeutics Inc. Common Stock BCAX | RA CAPITAL MANAGEMENT L.P. | 7,279,739 11.500% | 323,746 (+4.65%) | Filing History |
| 2026-02-17 7:28 pm Purchase | 2026-02-12 | 13D | Evommune, Inc. EVMN | RA CAPITAL MANAGEMENT L.P. | 3,494,638 9.700% | 35,868 (+1.04%) | Filing History |
| 2026-02-17 7:21 pm Purchase | 2026-02-09 | 13D | SpyGlass Pharma, Inc. Common Stock SGP | RA CAPITAL MANAGEMENT L.P. | 8,022,639 24.100% | 8,022,639 (New Position) | Filing History |
| 2026-02-17 4:45 pm Purchase | 2025-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY | RA CAPITAL MANAGEMENT L.P. | 2,385,279 9.900% | 425,049 (+21.68%) | Filing History |
| 2026-02-17 4:43 pm Purchase | 2025-12-31 | 13G | Surrozen, Inc. SRZN | RA CAPITAL MANAGEMENT L.P. | 871,731 9.200% | 4,313 (+0.50%) | Filing History |
| 2026-02-17 4:41 pm Purchase | 2025-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | RA CAPITAL MANAGEMENT L.P. | 6,666,837 9.900% | 1,105,478 (+19.88%) | Filing History |
| 2026-02-17 4:39 pm Purchase | 2025-12-31 | 13G | Palisade Bio, Inc. PALI | RA CAPITAL MANAGEMENT L.P. | 15,746,829 9.900% | 5,811,068 (+58.49%) | Filing History |
| 2026-02-17 4:37 pm Sale | 2025-12-31 | 13G | Monopar Therapeutics Inc. MNPR | RA CAPITAL MANAGEMENT L.P. | 667,632 9.900% | -75,229 (-10.13%) | Filing History |
| 2026-02-17 4:35 pm Purchase | 2025-12-31 | 13G | LB Pharmaceuticals Inc Common Stock LBRX | RA CAPITAL MANAGEMENT L.P. | 2,208,604 8.700% | 533,604 (+31.86%) | Filing History |
| 2026-02-17 4:33 pm Sale | 2025-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -6,045,351 (Position Closed) | Filing History |
| 2026-02-17 4:31 pm Purchase | 2025-12-31 | 13G | Invivyd, Inc. IVVD | RA CAPITAL MANAGEMENT L.P. | 28,857,208 9.900% | 7,518,920 (+35.24%) | Filing History |
| 2026-02-17 4:29 pm Purchase | 2025-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC | RA CAPITAL MANAGEMENT L.P. | 6,649,973 9.900% | 596,013 (+9.85%) | Filing History |
| 2026-02-17 4:27 pm Sale | 2025-12-31 | 13G | Eledon Pharmaceuticals, Inc. ELDN | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -3,566,338 (Position Closed) | Filing History |
| 2026-02-17 4:25 pm Sale | 2025-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | RA CAPITAL MANAGEMENT L.P. | 2,611,733 6.000% | -1,255,000 (-32.46%) | Filing History |
| 2026-02-17 4:23 pm Purchase | 2025-12-31 | 13G | Contineum Therapeutics, Inc. Class A Common Stock CTNM | RA CAPITAL MANAGEMENT L.P. | 2,179,711 7.200% | 57,711 (+2.72%) | Filing History |
| 2026-02-17 4:21 pm Purchase | 2025-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | RA CAPITAL MANAGEMENT L.P. | 1,939,065 9.900% | 552,898 (+39.89%) | Filing History |
| 2026-02-17 4:19 pm Sale | 2025-12-31 | 13G | Arcellx, Inc. ACLX | RA CAPITAL MANAGEMENT L.P. | 1,267,156 2.200% | -1,520,171 (-54.54%) | Filing History |